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Background/aim: The use of Transcranial Magnetic Stimulation (TMS) in the add-on treatment of patients with treatment-resistant
depression (TRD) is becoming more common. This study aims to investigate the efficacy of TMS on depression and accompanying
anxiety symptoms among patients with TRD.
Materials and methods: The current study was conducted with 38 patients diagnosed with TRD. The patients were randomly divided
into two groups and received 20 sessions of high-frequency (10Hz) TMS and 20 sessions of sham TMS to the left dorsolateral prefrontal
cortex in a double-blind and cross-over fashion without a change in their pharmacotherapy. In the clinical evaluation, Hamilton
Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) were carried out three times in total: before, crossover phase, and at the end of the treatment.
Results: A statistically significant decrease was found in the HAM-D and HAM-A in the group who were actively stimulated in the
cross-over phase of the study. While there was a significant decrease in the HAM-A in the group who received sham stimulation, the
decrease in the HAM-D was not statistically significant. Group comparisons revealed a statistically significant decrease in HAM-D in
the group who were actively stimulated compared to the group receiving sham stimulation. At the end of the study, 63% of 38 patients
responded to treatment, 15% partially responded, and 42% reached remission.
Conclusion: This randomized, double-blind, sham-controlled, cross-over study revealed that TMS is superior to sham-TMS, provides
clinically significant improvement when implemented besides pharmacotherapy among patients with treatment-resistant depression,
and is beneficial for accompanying anxiety symptoms.
Key words: Depression, resistance, treatment, transcranial magnetic stimulation

1. Introduction
Treatment-resistant depression (TRD) is generally defined
as a condition where patients with major depressive
disorder (MDD) do not respond to at least two distinct
and appropriate antidepressant treatments of adequate
doses and duration [1,2]. STAR*D (Sequenced Treatment
Alternatives to Relieve Depression) study conducted with
4000 patients uncovered that one-third of the patients with
MDD could not reach remission even after four aggressive
treatment strategies [3]. Treatment strategies include
replacing the current antidepressant with a different one
from another group, prescribing potentiator drugs (mood
stabilizers, atypical antipsychotics, thyroid hormones,
psychostimulants), and trying other options such as
Electroconvulsive Therapy (ECT). Transcranial Magnetic
Stimulation (TMS) treatment is also considered one of the
alternative strategies in TRD [4–7].
Transcranial magnetic stimulation (TMS) is a
neuromodulation technique that aims to create a magnetic

field strong enough to stimulate neurons in the target area.
It is used in many psychiatric and neurological diseases
for diagnosis and treatment purposes [8,9]. Although the
mechanism of action of TMS in depression is not clear,
changes in membrane potential, changes in the release
of neuromodulators (dopamine, etc.) and neurotrophic
factors (BDNF, etc.), neuroplasticity, neurogenesis,
cortical excitability, and neuromodulation are assumed
[10]. The United States Food and Drug Administration
(FDA) approved TMS treatment in patients with TRD in
2008 [11].
Patients who did not respond to treatment despite
using two antidepressants, one from the selective
serotonin reuptake inhibitor (SSRI) and the other from
the serotonin-norepinephrine reuptake inhibitor (SNRI)
for at least eight weeks, and currently using SNRI were
defined as treatment-resistant depression and included in
the study. We aimed to determine the treatment efficacy of
randomized, double-blind and cross-over, high-frequency
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(10Hz) TMS to the left dorsolateral prefrontal cortex
(DLPFC) twice a day for a total of 20 sessions and a total
of 20 sessions of sham TMS twice a day and examine the
effect on anxiety symptoms accompanying MDD.
The present study was based on the thesis study
titled “Efficacy of transcranial magnetic stimulation in
treatment-resistant depression”.
2. Materials and methods
2.1. Participants
The study sample consisted of outpatients without any
neurological disease between the ages of 18–65 who were
admitted to outpatient clinics of Pamukkale University
Faculty of Medicine, Department of Psychiatry between
August 2018 and April 2019, and diagnosed with MDD
in accordance with the DSM-5 diagnostic criteria. All
patients who were deemed unresponsive to treatment
despite using at least two antidepressants, one from the
SSRI and the other from the SNGI, of adequate doses for
at least eight weeks and who met the inclusion criteria
were invited to participate in the study. The study excluded
patients having psychiatric disorders such as psychotic
disorder, bipolar disorder, anxiety disorder, alcohol and
substance abuse, dementia, and mental retardation, those
who are at high risk of suicide, diagnosed with severe
MDD with psychotic features, received ECT treatment in
the last six months, previously received TMS treatment,
and patients with a pacemaker, intracranial implant,
foreign bodies, metals or magnetic implants. During
the study period, no changes were made in terms of
doses or active substances in the treatment regimen for
at least eight weeks. Once they received the necessary
information, 42 patients with mild major depression who
gave their consent to participate were included in the
study. The present study was completed with 38 patients.
At the beginning of the study, two patients had to leave
the study because of transportation issues when visiting
the hospital and two others left stating that they did not
benefit from the treatment. Patients using 150–300 mg of
venlafaxine per day or 60–120 mg of duloxetine per day
for at least eight weeks were divided into two groups in
a randomized, double-blind fashion. Venlafaxine dosage
was adjusted to 75 mg/day for two patients in one group
due to sexual side effects and high blood pressure.
According to the double-blind technique, the researchers
did not know which group the patients belonged to. Only
TMS technician knew groups and TMS application (sham
or real). The TMS technician, either, had no knowledge of
patient data. One (A) of the two groups first received TMS
(20,000 pulses in total) and then sham treatment (20,000
sham pulses in total) while the other group (B) was first
administered sham treatment (20,000 sham pulses in
total) and then TMS (20,000 pulses in total). A total of 20

sessions of cross-over, high-frequency (10Hz) TMS to the
left dorsolateral prefrontal cortex (DLPFC) twice a day
and a total of 20 sessions of sham TMS twice a day were
maintained in both groups for four weeks.
The current study was carried out in accordance with
the Declaration of Helsinki and was approved by the Ethics
Committee of Pamukkale University with the decision
letter dated 17.01.2018 and numbered 601116787020/4288.
2.2. TMS and sham TMS protocol
In this study, the protocol planned to test the efficacy of
TMS plus medication versus the efficacy of sham TMS
plus medication. TMS treatment protocol was performed
in the TMS unit of Pamukkale University Psychiatric
Hospital by a psychiatric nurse who has a certificate of
practice for TMS, using the Neuro-MS/D (Neurosoft
Ltd., Russia) device with figure-of-eight coils, under
appropriate physical conditions. In the first session, the
resting motor threshold was determined based on the
presence of involuntary contractions in the contralateral
fingers with a gradual increase in stimulation of the
middle interauricular band from the vertex to 5cm lateral.
As a result, 110% of the motor threshold was assigned to
be the intensity of treatment administration. The site of
treatment administration was based on the “5 cm rule”. In
line with this rule, 5 cm anterior on the parasagittal plane
from the motor cortex point where the motor threshold
was determined was regarded as the administration site.
This area corresponds to the left DLPFC. The 5cm method
is one of the most commonly used and most practical
methods to find the projection of the left DLPFC [12].
After assigning the left DLPFC as the administration site,
the coil was placed on the scalp at an angle of 45° to the
sagittal band.
We know that sham TMS may be administered with
the same coil used in actual stimulation by placing the
coil away from the scalp at a 45° angle (90° angle to the
sagittal band). In this way, patients experience a sound
and sensory effect similar to the actual administration;
however, the cortical structures below the area where
the coil is placed are not stimulated at all [13,14]. The
above-mentioned method was utilized for the sham
administration, and the same coil and parameters of the
actual application were used; however, unlike the actual
procedure, the coil was placed away from the scalp at a
45° angle.
Each TMS session was performed in 25 consecutive
sequences at 10Hz frequency, with 40 pulses in each
sequence lasting 2.5 s, and with a 20-s gap between the
sequences. Each session lasted approximately 9–10 min.
TMS is administered only on weekdays as 20 sessions for
two weeks, two times a day, and 10 sessions a week. The
same parameters apply to sham treatment sessions.
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2.3. Measurement tools
The sociodemographic data form prepared by the
researchers was completed with the patients in faceto-face interviews to question their sociodemographic
characteristics. In addition, Hamilton Depression Rating
Scale (HAM-D) and Hamilton Anxiety Rating Scale
(HAM-A) were carried out three times in total: before the
treatment, during the treatment (cross-over phase), and at
the end of the treatment.
2.3.1. Hamilton Depression Rating Scale (HAM-D)
It is a 17-item scale developed by Hamilton in 1960 to
measure the severity of depression. The validity and
reliability of its Turkish version are established [15,16]. It
is the most common method used to assess the level of
depression, symptom distribution, and changes in severity.
The total score of the scale ranges from 0 to 53, and high
scores indicate an increase in the severity of depression
[17].
2.3.2. Hamilton Anxiety Rating Scale (HAM-A)
The scale was developed by Hamilton in 1959 to
determine the level of anxiety and symptom distribution
in individuals and to measure the changes in severity. The
validity and reliability of its Turkish version are ensured.
Based on the total score, 17 points or less are considered
mild, 18–24 points moderate, and 25 points and above
severe [18].
2.3.3 Determining the response to treatment
A decrease of 50% or more in HAM-D scores compared
to the initial scores was defined as a response, a decrease
of 25%–50% as a partial response, and a decrease of
less than 50% as nonresponse. Patients needed to
have a HAM-D score of 7 or below in order to achieve
“remission”. A HAM-A score of 7 and below, in which the
accompanying anxiety level was assessed, was considered
a recovery.
2.4. Statistical analysis
The data of the present study were analyzed with the
SPSS (Statistical Package for the Social Sciences version
22, Chicago, IL, USA) software. Continuous variables
are given as mean ± standard deviation while categorical
variables as numbers and percentages. Independent
samples t-test was used to compare independent group
differences when parametric test assumptions were met.
On the other hand, Mann-Whitney U test was utilized
when parametric test assumptions were not met. When
parametric test assumptions were met, paired samples
t-test was used, and when these assumptions were not
met, Wilcoxon test was performed in dependent groups.
Categorical variables were assessed with the Chi-square
test. Statistical significance was set at p-value of <0.05 at a
95% confidence interval in all analyses.
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3. Results
3.1. Sociodemographic and clinical characteristics
A total of 38 patients, 32 (84.2%) females and 6 (15.8%)
males, were included in the study. The mean age of
the patients was 44.6 ± 11.5 (18–65). Table 1 shows the
sociodemographic characteristics of the patients who
were divided into groups A (first receiving TMS and then
sham-TMS) and B (first receiving sham-TMS and then
TMS) based on the cross-over of TMS administration
in a randomized, double-blind fashion. The mean ages
for groups A and B were 43.7 ± 14.2 (18–65) and 45.6 ±
7.8 (33–62), respectively, which is statistically similar (p
= 0.608). While the groups were also statistically similar
in terms of gender, marital status, educational level, the
people they live with, smoking and/or alcohol use (p >
0.05), the employment rate of group B was statistically
significantly lower compared to group A (p = 0.039).
The clinical characteristics of all patients are presented
in Table 2. The groups were statistically similar in disease
onset age, the number of depressive episodes, duration of
the last depressive episode, duration of SNRI use for the
last depressive episode, history of additional psychiatric
illness, history of inpatient treatment, type of SNRI
used by the patients during treatment, use of additional
psychiatric medication, history of suicide attempt,
history of psychiatric illness in first-degree relatives, and
history of physical illness (p > 0.05). The venlafaxine and
duloxetine dosages of group A were significantly higher
compared to the other group (p = 0.004 and p = 0.0001,
respectively). Comorbidity was detected in five patients:
OCD in remission in two patients, social phobia in one,
somatization disorder in one, and impulse control disorder
in one.
The pretreatment HAM-D and HAM-A scale scores of
the patient groups are presented in Table 3. The two groups
were statistically similar (p > 0.05).
3.2. Assessment of TMS
Table 3 shows the changes in scale scores before the
study (week 0), during the cross-over stage (week 2), and
at the end of the study (week 4). When the two groups
were analyzed independently of each other, a statistically
significant decrease was found in group A compared
to HAM-D, both at the end of TMS and at the end of
sham-TMS (p = 0.004 and p = 0.034). While there was no
significant difference in group B at the end of sham-TMS
compared to HAM-D, a statistically significant decrease
was found at the end of TMS (p = 0.018).
For group A, HAM-A total score decreased
significantly at the end of TMS while HAM-A psychic
subscores decreased significantly at the end of shamTMS (p = 0.027 and p = 0.027). The decrease in HAM-A
somatic subscores was not statistically significant at the
end of TMS or sham-TMS. For group B, HAM-A total
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Table 1. Sociodemographic characteristics of groups.
Group A
Mean±SD
Age
Female
Male
Single
Marital status
Married
Divorced
Primary school
Secondary school
Education
High school
University
Alone
People living with
With family
Unemployed
Working status
Working
No
Smoking
Yes
No
Drinking alcohol
Yes
Gender

Group B

p

45.6 ± 7.8

0.608

Mean±SD
43.7 ± 14.2
n

%

n

%

17
3
5
10
5
12
2
2
4
4
16
9
11
16
4
19
1

85
15
25
50
25
60
10
10
20
20
80
45
55
80
20
95
5

15
3
0
13
5
7
2
4
5
2
16
14
4
14
4
17
1

83.3
16.7
0
72.2
27.8
38.9
11.1
22.2
27.8
11.1
88.9
77.8
22.2
77.8
22.2
94.4
5.6

score decreased significantly at the end of sham-TMS while
HAM-A psychic subscores decreased significantly at the
end of TMS (p = 0.0001 and p = 0.047). The decreases in
HAM-A somatic subscores were not statistically significant
at the end of TMS or sham-TMS. Decreases in all scales and
subscales were statistically significant in both groups before
the study (week 0) and at the end of the study (week 4).
When the two groups were compared with each other,
HAM-D and HAM-A scale scores at weeks 0, 2, and 4,
were found to be statistically similar (p > 0.05) (Table 4).
The analyzes conducted by examining the change in the
scale scores (Table 5) pointed out that group A’s HAM-D
score decreased by 6.85 ± 3.93 points after TMS during
the measurements in the weeks 0–2 while there was
a decrease of 4.16 ± 4.84 points in group B after shamTMS. A significant difference was discovered between
the decreased rates of HAM-D scores of the two groups
after TMS and sham-TMS (p = 0.032). The groups were
statistically similar with the changes in HAM-D scores at
weeks 2–4 and 0–4 and HAM-A scores compared to all
measurement weeks (p > 0.05).
When all patients were divided into two groups based on
the type of drug administered (venlafaxine, duloxetine),
no significant difference was found between the first and
last measured HAM-D scores (p = 0.552 and p = 0.941)

0.888
0.071

0.574

0.453
0.039
0.867
0.939

and HAM-A (total, psychic, and somatic) scores of the two
groups (p > 0.05).
3.3. Evaluation of response to treatment
For group A, 6 (30%) patients responded to treatment after 20
sessions of TMS, and a total of 13 (65%) patients responded
to treatment with 20 additional sessions of sham-TMS. For
group B, 4 (22.2%) patients responded to treatment at the
end of sham-TMS, and 7 (38.9%) other patients responded
to treatment during TMS. Therefore, a total of 11 (61.1%)
patients responded to treatment in this group.
When all of the patients were evaluated as a whole
without making any distinctions between the groups, 24
(63%) patients responded to treatment, 6 (16%) patients
partially responded, 8 (21%) patients did not respond to
treatment, in addition to that, 16 (42.1%) patients reached
remission at the end of the study.
3.4. Assessment of side effects
No serious side effects were observed in any patient. The
most common side effect is a headache with a rate of 21%
(n = 8). In addition, 1 (2.6%) of the patients described
tinnitus, and 1 (2.6%) reported drowsiness. There was no
need for medical intervention in any of the patients who
reported side effects. Moreover, no patient discontinued
the study for this reason.
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Table 2. Clinical characteristics of the groups.
Clinical characteristics

Group A

Group B

p

Disease onset age (Mean±SD)

33.8 ± 14.4

31.8 ± 8.7

0.849

Number of depressive episodes (n, %)

3.1 ± 1.8

2.8 ± 2

0.875

Last depressive episode duration (month) (Mean±SD)

5.1 ± 3.2

5.3 ± 2.8

0.964

SNRI usage time in the last episode (week) (Mean±SD)
Psychiatric illness history (n, %)
Inpatient history (n, %)
Suicide
(n, %)
Psychiatric illness history (1st-degree relatives)
(n, %)
Physical illness history (n, %)
SNRI
(n, %)

17.5 ± 14.9

18.8 ± 19.5

No

17

94.4

16

80

Yes

1

5.6

4

20

No

17

94.4

17

85

Yes

1

5.6

3

15

No

14

77.8

17

85

Yes

4

22.2

3

15

No

11

61.1

10

50

Depression

5

27.8

5

25

Other psychiatric illness

2

11.1

5

25

No

7

38.9

13

65

Yes

11

61.1

7

35

Venlafaxine

12

66.7

9

45

Duloxetine

6

33.3

11

55

0.930
0.188
0.344
0.566

0.540

0.107
0.180

Venlafaxine dose (Mean ± SD)

225±64.9

150±45.2

0.004

Duloxetine dose (Mean ± SD)

92.7±28.3

80±30.9

0.0001

Psychiatric treatment
(n, %)

No

12

66.7

10

50

Yes

6

33.3

10

50

Table 3. Evaluation of the changing scale scores of the groups during the treatment process.

Group

Group A

Group B

Process / p

HAM-D

HAM-A
Psychic

Somatic

Total

Mean±SD

Mean±SD

Mean±SD

Mean±SD

0.week

20.2 ± 3.3

7.7 ± 3.1

7.8 ± 4.5

15.5 ± 6.9

2.week

13.4 ± 5.7

5.3 ± 2.4

5.5 ± 3.8

11.5 ± 5.5

4.week

9.5 ± 5.1

3.4 ± 2

3.9 ± 3

7.3 ± 4.7

p1

0.004*

0.291

0.707

0.027*

p2

0.034*

0.027*

0.098

0.291

p3

0.0001*

0.0001*

0.003*

0.0001*

0.week

20.5 ± 3.4

7 ± 1.4

6.4±2.5

13.4±2.9

2.week

16.3 ± 6.9

4.7 ± 1.6

4.5±2.7

8.5±3.5

4.week

9.9 ± 7.6

3 ± 1.7

2.8±2.4

5.9±3.8

p1

0.073

0.166

0.073

0.0001*

p2

0.018*

0.047*

0.137

0.116

p3

0.0001*

0.0001*

0.0001*

0.0001*

p1: p-value between prestudy–2. weekp2: p-value between 2.week–4.weekp3: p-value between prestudy and 4 weeks
*p < 0.05
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Table 4. Evaluation of the changing scale scores during the treatment process according to the groups.
Scale
HAM-D

Psychic

HAM-A

Somatic

Total

Process

Group A (Mean±SD)

Group B (Mean±SD)

p

0.week

20.2 ± 3.3

20.5 ± 3.4

0.823

2.week

13.4 ± 5.7

16.3 ± 6.9

0.164

4.week

9.5 ± 5.1

9.9 ± 7.6

0.758

0.week

7.7 ± 3.1

7 ± 1.4

0.613

2.week

5.3 ± 2.4

4.7 ± 1.6

0.582

4.week

3.4 ± 2

3 ± 1.7

0.529

0.week

7.8 ± 4.5

6.4 ± 2.5

0.274

2.week

5.5 ± 3.8

4.5 ± 2.7

0.668

4.week

3.9 ± 3

2.8 ± 2.4

0.282

0.week

15.5 ± 6.9

13.4 ± 2.9

0.566

2.week

11.5 ± 5.5

8.5 ± 3.5

0.053

4.week

7.3 ± 4.7

5.9 ± 3.8

0.316

Table 5. Evaluation of the difference between the scale scores in the treatment process according to the groups.
Scale
HAM-D

Psychic

HAM-A

Somatic

Total

Process

Group A (Mean±SD)

Group B (Mean±SD)

p

0. week–2. Week

6.85 ± 3.93

4.16 ± 4.84

0.032*

2. week–4. Week

3.85 ± 4.3

6.38 ± 5.84

0.171

0. week–4. Week

10.7 ± 5.19

10.55 ± 6.6

0.940

0. week–2. Week

2.35 ± 3.18

2.22 ± 2.36

0.890

2. week–4. week

1.9 ± 2.42

1.72 ± 1.7

0.857

0. week–4. Week

4.25 ± 3.69

3.94 ± 2.6

0.772

0. week–2. week

2.3 ± 3.46

1.94 ± 2.79

0.732

2. week–4. week

1.6 ± 2.28

1.61 ± 1.78

0.784

0. week–4. Week

3.9 ± 4.27

3.55 ± 3.27

0.784

0. week–2. week

3.95 ± 4.46

4.94 ± 3.65

0.214

2. week–4. week

4.2 ± 4.69

2.55 ± 4.84

0.295

0. week–4. week

8.15 ± 7.15

7.5 ± 4.86

0.748

*p < 0.05

4. Discussion
As a result of this study, 63% of 38 treatment-resistant
depression patients responded to TMS treatment, 15%
partially responded, and 42% reached remission. When
the groups were compared with each other, a statistically
significant decrease was observed in HAM-D in the TMS
group compared to the sham TMS group. Also, HAM-A
scores decreased in both groups.
HAM-D scores decreased by 6.85 ± 3.93 points in
group A and 4.16 ± 4.84 points in group B as a result of
the second-week evaluations of the current study. The

decrease in scale scores was significantly higher in group
A compared to group B. Similarly, Erbay et al. [19] found
statistically significant differences in HAM-D scores before
and after rTMS. Also, we showed that the rates of response
to treatment were significantly higher in the group receiving
TMS compared to those receiving sham-TMS. These results
suggest that TMS treatment is superior to sham-TMS,
which is in line with the results of meta-analyses [11,20].
Although sham-TMS protocol was performed at a 45°
angle in the present study, which minimizes the effects of
actual stimulation [13], some studies argue that sham-TMS
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may create partially active stimulation effects that can bring
about the intended clinical improvement. Some studies
emphasized that sham-TMS has some antidepressant
effects, and this placebo effect is generally observed among
patients with mild-to-moderate MDD [21].
HAM-D scores decreased significantly in both groups
between the 2nd and 4th weeks of the study. This decrease
was similar in both groups: 3.85 ± 4.3 points in group A
and 6.38 ± 5.84 points in group B. Although there was no
statistical difference, the reason why points are higher in
group B may be that group B received active TMS treatment
in the last 2 weeks of the study. A partial and complete
response to treatment increased from 65% to 85% in group
A and from 28% to 72% in group B based on HAM-D. These
results suggest that TMS is beneficial in TRD. Kedzior et al.
[22] investigated the antidepressant effect of TMS without
active maintenance therapy in a meta-analysis of 16 doubleblind, randomized, sham-controlled studies in the literature.
They found that the antidepressant effect persisted longer
in the follow-up of patients who have had lower disease
severity, unipolar depression, no psychotic symptoms,
showed resistance to treatment, and taken antidepressant
medication at the beginning. In long-term follow-up (8–16
weeks), the efficacy was lower compared to those with a
short (1–4 weeks) follow-up period [22]. A study conducted
by Theleritis et al. revealed a further decrease in HAM-D
scores in the 2-week follow-up of 89 patients with TRD
after the 3-week TMS treatment. This decrease has been
attributed to a delayed effect of TMS in some patients [23].
At the end of the 2nd week, there was a significant
decrease in HAM-A scale total scores in both groups
while the psychic and somatic subscales declined at a
nonsignificant level. When the anxiety level of the patients
was compared between the groups, there were similarly
minimum decrease rates at the end of the 2nd week. This
indicates that TMS was not superior to sham-TMS with
regards to anxiety symptoms accompanying depression
in the current study. While some studies [24] support this
result, there are many others [25,26] that argue the opposite
in the literature. According to the results of a recent metaanalysis, TMS is effective in generalized anxiety disorder,
but this field needs to be supported by more research [27].
At the end of the current study, both groups experienced
a decrease in the initial and final HAM-D and HAM-A
scores. Patients (63%) responded to treatment and 42.1%
achieved remission. When we look at the literature, similar
to our study, it is mentioned that TMS is superior to sham
TMS in response and remission rates, with an average of
30%–60% [6,28]. Bolu et al. [28] found that at similar ages,
response rates were 26.1%–44.7% and MDD responds to
treatment better than other psychiatric disorders.

The majority of the patients in the study were female
(n = 32) and middle-aged 44.6 ± 11.5 (18–65) individuals.
Epidemiological studies generally emphasize that major
depressive disorder is more common, especially, in the
middle-aged group, and is twice as common among women
1
Lingeswaran showed that the antidepressant effect of
TMS treatment is more prominent at a younger age [29].
It has been reported that the brain undergoes atrophy and
the distance between the scalp and the prefrontal cortex
increases due to aging, reducing the electrical activity of
the magnetic field created by TMS in the targeted cortical
tissue, which in turn causes fewer neuroplastic changes [30].
All the patients in our study continued the
antidepressant treatment they were receiving before TMS
started at the same dose. For group A, the mean daily doses
of both venlafaxine and duloxetine were significantly
higher compared to the other group. Although this result
is due to randomization, it leads to questioning the level of
efficacy between the 2 groups. In this study, no differences
were observed in the treatment of TMS by medication
type. For group B, two patients whose venlafaxine dosage
was reduced (75mg/day) due to side effects also responded
to TMS treatment. Most of the studies reported that the
application of TMS alongside existing pharmacological
treatment has a higher treatment efficacy than those which
only provide TMS [31,32]. The current study administered
TMS in addition to pharmacotherapy to achieve a better
response to treatment.
All patients tolerated TMS successfully with the
following specifications: 2 sessions per day with a frequency
of 10Hz (high), 110% motor threshold, and 1000 pulses
per session. Nonserious side effects were observed in 10 of
the patients. In the present study, the most common side
effect was headache, which is consistent with the literature
[11]. Headache may be caused due to having to maintain
the posture during the application and the magnetic field.
Contrary to studies pointing out that the application of
TMS at high frequencies and in short intervals is feasible
and safe, some studies report that the risk of seizure, one of
the most serious side effects, increases in these conditions
[11].
O’Reardon et al. extended the duration of TMS
treatment to 4–6 weeks and found that the efficacy of the
treatment increased with longer periods of stimulation
[33]. However, as the duration of treatment is increased,
the rate of discontinuation also increases [34]. The current
study implemented a 4-week treatment period to minimize
discontinuation rates. It has been suggested that more
sessions of TMS and a higher number of pulses per day may
accelerate the antidepressant effect and decrease the rates
of discontinuation during the TMS treatment [11]. Four of

World Health Organization (2017). Depression and Other Common Mental Disorders Global Health Estimates [online]. Website https://apps.who.
int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf [accessed 01 June 2022].
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the 42 patients left at the beginning of the present study, and
there was no discontinuation in the following period. In
their sham-controlled study where 1 and 2 sessions of TMS
treatment were administered per day, Theleritis et al. [23]
found that patients who received 2 sessions of TMS per day
had a higher response and remission rates than those who
received TMS once a day after 3 weeks of treatment. The
number of sessions and daily pulses are important factors
that increase the efficacy of treatment. While evaluating
the positive effect of increasing the number of TMS daily
sessions on remission rates, there is also information that
anxiety and irritability may increase [10].
In studies investigating the efficacy of TMS among
patients with TRD are quite heterogeneous. In treatments
administering different time and different pulse numbers
each have a positive effect on the treatment and remission
rates to a varying degree [35–37]. The rates of TMS treatment
response varies, which may be caused by many reasons.
For instance, as the number of pulses, motor threshold,
frequency, and duration of TMS application the lack of
standardization regarding the indications and protocol
of TMS application is a crucial issue, it is not possible to
guarantee that the region to be stimulated (DLPFC) is
correctly determined. Another issue is that methods to
manage clinical differences or the predictors of response
to treatment are not known because the mechanism of
action of TMS is not yet clearly defined. Differences in
psychotherapy and/or pharmacotherapy received by
patients during and after TMS, tolerance to treatment, the
approach assumed by healthcare professionals, and the
differences in the evaluation scales used in the studies are
other important issues to consider. In the present study,
patients’ beliefs about a new treatment, spending one-to-

one more time with patients during the application, and
the high number of patients with moderate MDD may
have increased the efficacy of TMS treatment.
Limitations of the current study include the following:
the predominance of female patients participating in the
study, the small number of samples, and the inability to
isolate the effect of TMS due to its administration alongside
the drug treatment. Also, the neuro-navigation method
and sham coil are not used for determining the area where
TMS will be applied because of their high cost. Another
limitation is that the follow-up studies of the patients are
not part of the current study.
In conclusion, TMS is a low-cost, well-tolerated somatic
treatment method with few side effects in TRD where the
treatment rate is low with current pharmacotherapies. The
present study demonstrated that TMS, in its randomized,
double-blind, sham-controlled cross-over method, is
superior to sham-TMS and is beneficial for depression
and accompanying anxiety symptoms. However, further
research is needed in different depression subgroups with
larger sample sizes and supported by follow-up studies
.
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